pharmaceutical giant Cipla has introduced a three-in-one aids drug called Triomune. The new drug is a combination of stavudine, lamivudine and nevirapine. Cipla could synthesise the drug because Indian laws allow generic copies to be made. The generic drug would remain one of its kind, as the patent holders of the three drugs are unlikely to form an alliance for a similar offer. Triomune has several advantages over the three drugs. With its introduction, the treatment cost has been slashed from Rs 2,000 to Rs 1,800. Along with this, the dosage has also been reduced -- from six tablets per day to only two. This will immensely help those patients who are forced to forgo one or two of the aids drugs due to financial constrains. "Patients who do not take the entire dosage of their treatment risk their own health," said Julian Meldrum, international editor of the uk -based National aids Manual. Cipla plans to market the pill to developing countries.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
.png)
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.